Published in Medical Letter on the CDC and FDA, March 15th, 2009
Net product sales of ENTEREG® (alvimopan) recognized for the quarter and year ended December 31, 2008 were approximately $1.1 million and $1.2 million, respectively. Under Adolor’s current revenue recognition policy, revenue related to a customer shipment is deferred until subsequent re-orders by that customer. For the year ended December 31, 2008, net product sales were recognized based on re-orders from approximately 185 hospitals. Total net shipments for the quarter and year ended December 31, 2008 were approximately $1.6 million and $2.2 million,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA